 Home > Active Ingredient News > Antitumor Therapy > NEJM: Nivolumab plus chemotherapy as neoadjuvant therapy for resectable lung cancer can greatly improve patient outcomes

NEJM: Nivolumab plus chemotherapy as neoadjuvant therapy for resectable lung cancer can greatly improve patient outcomes

 Last Update: 2022-05-21
 Source: Internet
 Author: User

Tags

unos gluten free

2 4 lv6 label

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

For resectable non-small cell lung cancer ( NSCLC ), neoadjuvant or adjuvant chemotherapy offers some benefit over surgery alone

Lung cancerNSCLC

This study is an open-label, randomized, controlled phase 3 clinical trial that enrolled patients with stage IB-IIIA resectable NSCLC who were randomly assigned to receive nivolumab plus platinum-based chemotherapy or only Adjuvant platinum-based chemotherapy followed by surgical resection

The primary endpoints were event-free survival and pathological complete response rate

The median event-free survival was 31.

For patients with resectable non-small cell lung cancer, compared with chemotherapy alone, nivolumab combined with chemotherapy neoadjuvant therapy can significantly prolong event-free survival, significantly increase the rate of pathological complete response, and do not increase the incidence of adverse events

Original source:

Original Source: Original Source:

Forde Patrick M, Spicer Jonathan, Lu Shun et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.